LEXICON PHARMACEUTICALS, INC. Environmental Analytics
Environmental and financial analysis dashboard for LEXICON PHARMACEUTICALS, INC.. Industry: MANUFACTURING
Company Overview for LEXICON PHARMACEUTICALS, INC.
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.00m
Operational Environmental Cost Intensity
1.43%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-0.10m
Decoupling Rate (2020-2022)
-85%
Adjusted EBITDA
$-99m
Adjusted EBITDA Margin
-71,035%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -98.70% | 63.17% | 790.98% | ||
| 0.13% | 0.14% | 0.48% | 0.50% | |
| -97.64% | -18.41% | 897.24% | ||
| 0.29% | 0.55% | 0.96% | 1.11% | |
| $0m | $0m | $0m | $0m | |
| -97.97% | -2.10% | 861.82% | ||
| 0.42% | 0.68% | 1.43% | 1.61% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-71,035%
Adjusted EBIT Margin
-71,342%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$24m | $0m | $0m | $1m | |
| -98.75% | -53.33% | 757.14% | ||
$65m | $88m | $100m | $164m | |
| 271.27% | 29181.88% | 71133.81% | 13676.74% | |
$-41m | $-87m | $-99m | $-163m | |
| -171.27% | -29081.88% | -71033.81% | -13576.74% | |
$-44m | $-88m | $-100m | $-163m | |
| -183.50% | -29179.87% | -71341.01% | -13622.76% | |
| ENVIRONMENTAL COST DATA | ||||
$0m | $0m | $0m | $0m | |
| 0.42% | 0.68% | 1.43% | 1.61% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-41m | $-87m | $-99m | $-163m | |
| -171.69% | -29082.56% | -71035.25% | -13578.35% | |
$-44m | $-88m | $-100m | $-163m | |
| -183.92% | -29180.55% | -71342.44% | -13624.37% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.48%
Scope 2 (% of Sales)
0.96%
Operational Environmental Cost Intensity
1.43%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
LEXICON PHARMACEUTICALS, INC. | US | $0m | 1.43% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022